Istesso

News

Shares in the UK's IP Group slid today after it said that an arthritis drug in development at portfolio company Istesso had failed a phase 2b trial.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.